Aldosterone, 24-Hour Urine

CPT: 82088
Print Share

Special Instructions

Instructions for suppression/stimulation tests that involve serum aldosterone measurement can be found in the online Endocrine Appendix: Aldosterone Suppression.

Expected Turnaround Time

4 - 9 days

Related Documents

Specimen Requirements


Urine (24-hour)


10 mL

Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Plastic urine container with no preservative (Note: 1 g/L boric acid may be added as a preservative for other test without harm to aldosterone.)


Instruct the patient to void at 8 a.m. and discard the specimen. Then collect all urine including the final specimen voided at the end of the 24-hour collection period (i.e., 8 a.m. the next morning) into the plastic urine container. Screw the lid on securely. Transport the specimen promptly to the laboratory. Container must be labeled with patient's full name, date and time collection started, and date and time collection finished. pH must be 4 to 8.

Storage Instructions


Stability Requirements



Room temperature

7 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Patient Preparation

If patient is taking diuretics, antihypertensive drugs, cyclic progestational agents, estrogen, or licorice, results for aldosterone may not be interpretable. Patient should be on a diet containing 135 mmol (3 g) sodium per day for at least two weeks and preferably 30 days prior to testing.

Causes for Rejection

Incomplete 24-hour collection; original container with pH <2

Test Details


Study of adrenocortical-renin-angiotensin system; adrenal cortical function test; evaluate renal hypertension; diagnose Conn syndrome (primary aldosteronism); evaluate hypokalemia with hypertension


Urinary aldosterone measurements alone are of limited value in the diagnosis of hyperaldosteronism. Elevated levels mandate further investigation.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Reference Interval

• Pediatric:1,2

− 0 to 3 days: 0.00−5.00 μg/24 hours

− 4 days to 10 years: 0.00−8.00 μg/24 hours

− >10 years: 0.00−19.00 μg/24 hours

• Adults:

− Low sodium intake: 20.00−80.00 μg/24 hours

− Normal sodium intake: 0.00−19.00 μg/24 hours

− High sodium intake: 0.00−12.00 μg/24 hours

Additional Information

The renin-angiotensin system and potassium ion are the major regulators of aldosterone secretion, whereas ACTH and other POMC peptides, sodium ion, vasopressin, dopamine, ANP, α-adrenergic agents, serotonin, and somatostatin are minor modulators.1,2 Renin cleaves angiotensinogen, which is synthesized by the liver; to produce angiotensin I. Angiotensin I is, in turn, rapidly cleaved by angiotensin-converting enzyme (ACE) in the lung and other tissues to form angiotensin II. Angiotensin II stimulates aldosterone secretion and vasoconstriction. Factors that decrease renal blood flow, such as hemorrhage, dehydration, salt restriction, upright posture, and renal artery narrowing, increase renin levels which, in turn, raise aldosterone levels. In contrast, factors that increase blood pressure, such as high salt intake, peripheral vasoconstrictors and supine posture, decrease renin and aldosterone levels.3 Aldosterone promotes active sodium transport and excretion of potassium.

Hypokalemia increases and hyperkalemia decreases renin release.1 Potassium also directly increases aldosterone secretion by the adrenal cortex and aldosterone then lowers serum potassium by stimulating its excretion by the kidney. High dietary potassium intake increases plasma aldosterone and enhances the aldosterone response to a subsequent potassium or angiotensin II infusion.3

Primary hyperaldosteronism, also referred to as Conn syndrome, is caused by the overproduction of aldosterone by one or both of the adrenal glands.1,2 Historically, primary aldosteronism was considered to be an uncommon cause of hypertension. However, recent studies indicate that 10% to 15% of cases are associated with primary hyperaldosteronism.4 Secondary hyperaldosteronism is relatively common and can occur as the result of any condition that decreases blood flow to the kidneys (ie, renal artery stenosis), decreases blood pressure, or lowers plasma sodium levels. Secondary hyperaldosteronism may also be seen with cirrhosis, congestive heart failure, and toxemia of pregnancy.

Hyperaldosteronism increases reabsorption of sodium and loss of potassium by the kidneys, resulting in an electrolyte imbalance.1,5 The condition can be asymptomatic, although muscle weakness can occur if potassium levels are very low. A number of studies have suggested that high-normal aldosterone levels predict development of high blood pressure in normotensive subjects6 and that increased aldosterone action contributes to hypertension, cardiovascular fibrosis, and cardiac hypertrophy.5-7


1. Demers RM, Whitley RJ. Function of the adrenal cortex. In Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia, Pa: WB Saunders Co;1999:1530-1569.
2. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005 Jul; 186(1):1-20.16002531
3. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007 Oct; 13(8 Suppl B):S9-S20.17970613
4. Ten S, New M, Maclaren N. Clinical Review 130: Addison's disease 2001. J Clin Endocrinol Metab. 2001 Jul; 86(7):2909-2922.11443143
5. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008 Sep; 93(9):3266-3281.18552288
6. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004 Jul 1; 351(1):33-41.15229305
7. Stowasser M, Taylor PJ, Pimenta E, et al. Laboratory investigation of primary aldosteronism. Clin Biochem Rev. 2010 May; 31(2):39-56.20498828


Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am. 1994 Jun; 23(2):271-283. 8070422
Young WF Jr. Pheochromocytoma and primary aldosteronism: Diagnostic approaches. Endocrinol Metab Clin North Am. 1997 Dec; 26(4):801-827.9429861


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
004291 Aldosterone, Urine 289117 Aldosterone U,Random ug/L 1764-0
004291 Aldosterone, Urine 004293 Aldosterone,U, Timed ug/24 hr 1765-7

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at